摘要:

Southern blot analysis was performed with a panel of DNA probes to detect rearrangements of c-myc,bcl-1,bcl-2 andbcl-1 in 14 cases of B-cell non-Hodgkin's lymphoma (NHL) with a clonal cytogenetic rearrangement involving the chromosome 14q32 locus and no known donor chromosome [t(14;?)(q32;?)]. In our experience, 21% of all chromosomal abnormalities involving the 14q32 locus in B-cell NHL are of this type. We found oncogene rearrangements in five of the 14 cases:bcl-1 rearrangement on one mantle zone lymphoma,bcl-2 rearrangements in two follicular lymphomas, and c-mycrearrangements in two small noncleaved cell lymphomas. We conclude that a 14q32 + abnormality of unknown origin is a relatively frequent karyotypic finding in B-cell NHL. In one third of the cases, known oncogenes that have been previously described in reciprocal translocations involving the immunoglobulin heavy chain locus were shown to be involved in the 14q32 + abnormality. The translocations in the other cases are likely to have involved one of the above oncogenes with breakpoints not revealed by the probes employed, other known oncogenes, or oncogenes that have not yet been identified.

ISSN:1042-8194    

DOI:10.3109/10428199309147360

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Follicular lymphoma is often seen as an indolent disease with a reasonable medium-term survival. We have used the information in the Scotland and Newcastle Lymphoma Group database to devise an index which is easily calculated and differentiates patients into poor, intermediate and good prognostic groups with 5 year survivals of 24%, 61% and 86% respectively. The key factors at presentation are age, ECOG performance status, stage and the presence or absence of B symptoms or gastro-intestinal tract involvement. The use of such an index permits early identification of patients with a poor prognosis for whom more intensive treatment could be offered.

ISSN:1042-8194    

DOI:10.3109/10428199309147361

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

The main initial and evolutive variables of 133 patients with large-cell lymphoma treated with adriamycin-containing regimens were evaluated for prognostic significance. At the time of analysis, 66 patients had died with the median survival of the series being 48.9 months. Variables associated with poor prognosis in the univariate study were: lymphoma of immunoblastic subtype, advanced Ann Arbor stage, presence of B-symptoms, poor performance status, bulky disease (≥10cm), involvement of two or more extranodal sites, bone marrow infiltration, and high serum LDH levels. In the multivariate analysis, Ann Arbor stage (p<0.001), bulky disease (p= 0.004), performance status (p= 0.018), and histologic subtype (p= 0.021) retained their prognostic value. After excluding those patients with localized disease (stage I), the Ann Arbor staging system lost prognostic significance in favor of bone marrow infiltration (p= 0.009) and serum LDH (p<0.001). However, when response to treatment was included in the regression model, it proved to be the most important prognostic factor (p<0.001), followed by serum LDH (p= 0.004). On the other hand, when the analysis was restricted to complete responders, serum LDH at diagnosis was the only parameter useful to predict survival (p= 0.008). Finally, five recently proposed prognostic classifications were useful to separate different risk-groups of patients when applied to the series.

ISSN:1042-8194    

DOI:10.3109/10428199309147362

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Studies of peripheral blood lymphocytes (PBL) and plasma from patients with malignant lymphoma [Hodgkin's disease (HD) and non Hodgkin's lymphoma (NHL)] show that plasma soluble interleukin 2 receptor (sIL2R) levels are closely linked with disease status (normal volunteers (n= 15) 402±158u/ml; patients with Hodgkin's disease in remission (n= 4) 525±195 u/ml or with active disease (n= 11) 3026±1602 u/ml (p<0.001); patients with non Hodgkin's lymphoma in remission (n= 6) 462±202 u/ml, active disease (n=15) 2713±1755 u/ml, (p<0.001)) but no correlation between sIL2R and the inhibition of interleukin 2 (IL2) generated cytotoxicity for the cell line K.562. In only 1 of 15 patient plasma samples studied was there a dose dependent inhibition of IL2 generated cell killing. In a further patient, IL2 generated K562 killing was inhibited at all doses (500-3000 brmp units/ml); treatment of this plasma with anti-Interleukin 4 (αIL4) had no effect on the potent inhibitory activity of the plasma. Plasma sIL2R levels were markedly elevated in patients receiving IL2in vivo(pre treatment 520±170iu/ml, during treatment 5578±2564iu/ml,p= 0.05). The aetiology of immunosuppression in patients with lymphoma appears to be multi-factorial; although sIL2R correlates with disease activity it does not appear to directly mediate immunosuppression in most patients with malignant lymphoma.

ISSN:1042-8194    

DOI:10.3109/10428199309147363

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Chronic Lymphocytic Leukemia is a relatively uncommon hemopoietic malignancy in the Indian subcontinent. We have made an attempt to correlate the morphology of the marrow with staging and clinical course of the disease in 26 cases. Four out of 6 cases in Stage A showed a nodular/interstitial marrow pattern, while 18 out of 20 cases of stage B and C demonstrated a mixed/diffuse involvement of marrow. Cases showing a nodular/interstitial pattern had a relatively benign clinical course even without chemotherapy, while patients with diffuse/mixed marrow pattern required chemotherapy. Trephine histological pattern was found to be a good prognosticator and was useful in segregating cases requiring chemotherapy from those which do not.

ISSN:1042-8194    

DOI:10.3109/10428199309147364

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Interleukin 12 (IL12, NKSF-natural killer stimulatory factor) was found to stimulate natural killer (NK) cell activity of hairy cell leukemia (HCL) patients. Two patients not responding to IL12 stimulation were also resistant to interferon alpha (IFN alpha)-mediated augmentation of NK activity. IL12 also enhanced slightly the interleukin 2 (IL2)-induced cytotoxicity of HCL patients, while IFN alpha reduced the stimulatory effect of IL2. These data suggest that interleukin 12 has NK modulatory properties in HCL leukemia patients, which may be different from those of IFN alpha.

ISSN:1042-8194    

DOI:10.3109/10428199309147365

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

To evaluate its clinical efficacy as well as its biologic safety, human recombinant Erythropoietin (rh-Epo) was given to 19 patients with myelodysplastic syndromes (MDS) in an open non-randomized study. Among the seventeen evaluable patients only two showed an apparent hematologic response to rh-Epo treatment. In these patients hemoglobin levels increased from a mean pretreatment value of 8.5 and 8.4g/dl up to 11.7 and 11.3 g/dl respectively and remained relatively stable for several weeks. In one of these patients the transfusion requirement decreased from 4 to 1.5 units per month whereas the other had no transfusion requirement during the whole period of rh-Epo treatment. Interestingly, when the responding patients, after a“wash-out”period of at least ten weeks, received an additional course of rh-Epo results were less impressive. Before treatment the serum level of endogenous Epo was 18 and llOmU/ml in the two responding patients, whereas a mean value of 532 mU/ml (range 17-2797 mU/ml) was observed in non responders. The treatment of MDS patients with rh-Epo was clinically well tolerated since no relavent side effects were registered. Moreover, no evidence of harmful cytogenetic changes nor activation of myeloid growth factor genes, as determined by Northern blot analysis of GM-CSF and G-CSF gene expression, could be related to rh-Epo treatment. Overall, it appears that administration of rh-Epo is well tolerated but the therapeutic effects appear to be restricted to a minority of patients and a limited period of time.

ISSN:1042-8194    

DOI:10.3109/10428199309147366

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

The effects of bryostatin 1 (Bryo 1), a protein kinase C (PKC) activator, on proliferation, differentiation and macromolecular synthesis were investigated in the two cell lines EHEB and JVM-2, established from patients with chronic B-cell leukemia. Treatment with Bryo 1 inhibited the proliferation, DNA and RNA synthesis in a time- and dose-dependent fashion. The cells differentiated along the B-cell pathway to plasmacytoid cells as judged by morphological examination and increased their production and secretion of immunoglobulins. c-myc mRNA expression was induced in both cell lines. The phorbol ester TPA, a pharmacological PKC activator, had similar differentiation-inducing effects. The bio-modulators failed to induce significant alterations in the cell surface marker profile. Except for their surface markers, all parameters studied were more strongly altered in JVM-2 than in EHEB cells. JVM-2 was established from a patient with B-prolymphocytic leukemia (PLL), whereas EHEB originated from a case of B-chronic lymphocytic leukemia (CLL). These data support the notion that PLL cells appear to be activated B-cells, in contrast to the rather quiescent CLL cells. Since Bryo 1 lacks tumor-promoting activity, this naturally occurring compound, extracted from marine animals, has a potential role in the therapy of B-cell neoplasms as a differentiating agent.

ISSN:1042-8194    

DOI:10.3109/10428199309147367

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Treatment with ganciclovir was assessed in 13 patients who underwent allogeneic T-lymphocyte depleted bone marrow transplantation (BMT) for a variety of malignant hematological disorders and subsequently developed severe cytomegalovirus (CMV) disease without pneumonia. The manifestations of CMV disease appeared on days 23-105 (median 51) post BMT, and included gastrointestinal symptoms, weight loss, fever, disturbed liver function, leukopenia and thrombocytopenia. Ganciclovir was administered for 14 days, without the addition of intravenous immunoglobulins. Following therapy, the clinical manifestations subsided in most of the patients, while leukopenia, thrombocytopenia and liver dysfunction resolved in about half of the patients. One patient who experienced recurrent CMV disease responded to a second course of ganciclovir. Poor response to ganciclovir treatment was observed in 2 of the 3 patients with grade 4 graft-versus-host disease (GVHD). Our experience suggests that a 2-week course of ganciclovir may be effective in BMT recipients who develop severe CMV-associated disease without lung involvement, especially when there is no concommitant severe GVHD.

ISSN:1042-8194    

DOI:10.3109/10428199309147368

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor